Our strategy Two routes to proven medicines, run on one platform

Adventa Pharma works on two complementary development routes. One secures supply of medicines patients already rely on. The other improves how those medicines are given.

ANDA · Section 505(j) Sole-supplier generics

We target generic medicines with one or very few approved sources, where technical complexity keeps competition limited and reliable supply matters to hospitals and patients.

Complex injectables and hard-to-make dosage forms
Products with few or no approved generic suppliers
Portfolio choices that anticipate shortage risk
Durable, lower-competition positions for partners

NDA · Section 505(b)(2) Improved formulations of proven medicines

We build new versions of approved medicines that remove a barrier to use: a better formulation, a ready-to-use presentation, an improved salt or solid form, or a more convenient route.

Reliance on the reference product’s established safety and efficacy
Bridging studies in place of full clinical programmes
Own intellectual property and product differentiation
Branded economics at a fraction of new-drug risk

How we work One platform takes each molecule from proof to partner

Find the gapWe identify where a proven molecule falls short for patients, in supply, formulation or route.
Engineer the improvementFormulation and solid-state science, and complex manufacturing, build the better product.
Secure approvalComplete, reviewer-ready ANDA and 505(b)(2) filings with the US FDA.
Partner for launchWe hand approved products to commercial partners, ready for market, and support them after signature.